To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.
Also called NCT06901505
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 353 participants
- Sponsor
- Registry
-
NCT06901505
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT06901505. Randomized; no masking; primary purpose treatment. Start 2025-07-24 (actual); primary completion 2026-08-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
- Condition
- Anemia of Chronic Kidney Disease
- Intervention (Drug)
- Erythropoiesis-Stimulating Agent (ESA)
- Intervention (Drug)
- Vadadustat
- Lead sponsor
- Akebia Therapeutics
Record details
- Record id
cardio:ct-nct06901505- Content hash
1833a7181c4e14c5269d6ef0696772437cbcc6b772faadba805e237cf2f617e4